11.12.2017
Zugemailt von / gefunden bei: Hookipa (BSN-Hinweis: Lauftext im Original des Aussenders, Titel (immer) und Bebilderung (oft) durch boerse-social.com aus dem Fotoarchiv von photaq.com)
Vienna, Austria, 11 December 2017 - Hookipa Biotech AG (“Hookipa”), a clinical stage biotech company pioneering an innovative class of immune activation therapies for oncology and infectious diseases, today announced that it has raised $59.6 million (€50.0 million) in an oversubscribed Series C financing.
The round was led by an undisclosed blue chip U.S. public investment fund specializing in life sciences, alongside other new investors HBM Partners, Hillhouse Capital, Sirona Capital and strategic investor Gilead. All current Hookipa investors, Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners participated in the round.
The proceeds of the fundraising will be primarily used to progress two proof-of concept clinical trials of Hookipa’s lead development programs, a phase 2 study of the Company’s prophylactic Cytomegalovirus (“CMV”) vaccine in solid organ transplant patients, and a phase 1 study of its TheraT® based active immunization therapy in patients with head & neck squamous cell carcinoma. In addition, Hookipa plans to expand its technology platform into other disease areas, such as prostate cancer.
Hookipa’s arenavirus-based vector technologies TheraT® and Vaxwave® have been designed to infect dendritic cells and stimulate potent and long-lasting immune responses. HB-101, the Company’s Vaxwave®-based CMV vaccine successfully completed a phase 1 trial earlier this year, demonstrating safety and immunogenicity. TheraT® has been shown to elicit uniquely potent antigen-specific CD8+ cytotoxic T cell responses and strong tumor control in mice. TheraT® works by delivering tumor-associated antigen-specific immunization alongside the release of the alarmin interleukin-33 (IL-33), which is key in stimulating potent and protective CD8+ cytotoxic effector T lymphocytes.
Joern Aldag, Chief Executive Officer of Hookipa said: “Our vision is of a world in which the immune system actively controls infectious diseases and cancer, using monotherapy or combinations of medications. We welcome the funding and support from this group of leading current and new investors, who have recognized the potential, versatility, and uniqueness of our novel viral vector platform in this context. This financing allows us to progress two lead development programs through the major inflection points of clinical proof of concept, and to expand our clinical work to additional virology and oncology indications.”
8957
wiener_biotech_hookipa_sichert_sich_knapp_60_mio_dollar_frisches_kapital
Aktien auf dem Radar:Palfinger, Amag, SBO, Flughafen Wien, AT&S, Frequentis, EVN, EuroTeleSites AG, CA Immo, Erste Group, Mayr-Melnhof, S Immo, Uniqa, Bawag, Pierer Mobility, ams-Osram, Addiko Bank, Wiener Privatbank, SW Umwelttechnik, Oberbank AG Stamm, Kapsch TrafficCom, Agrana, Immofinanz, OMV, Österreichische Post, Strabag, Telekom Austria, VIG, Wienerberger, Warimpex.
(BSN-Hinweis: Lauftext im Original des Aussenders, Titel (immer) und Bebilderung (oft) durch boerse-social.com aus dem Fotoarchiv von photaq.com)192094
inbox_wiener_biotech_hookipa_sichert_sich_knapp_60_mio_dollar_frisches_kapital
Uniqa
Die Uniqa Group ist eine führende Versicherungsgruppe, die in Österreich und Zentral- und Osteuropa tätig ist. Die Gruppe ist mit ihren mehr als 20.000 Mitarbeitern und rund 40 Gesellschaften in 18 Ländern vor Ort und hat mehr als 10 Millionen Kunden.
>> Besuchen Sie 68 weitere Partner auf boerse-social.com/goboersewien
11.12.2017, 3275 Zeichen
11.12.2017
Zugemailt von / gefunden bei: Hookipa (BSN-Hinweis: Lauftext im Original des Aussenders, Titel (immer) und Bebilderung (oft) durch boerse-social.com aus dem Fotoarchiv von photaq.com)
Vienna, Austria, 11 December 2017 - Hookipa Biotech AG (“Hookipa”), a clinical stage biotech company pioneering an innovative class of immune activation therapies for oncology and infectious diseases, today announced that it has raised $59.6 million (€50.0 million) in an oversubscribed Series C financing.
The round was led by an undisclosed blue chip U.S. public investment fund specializing in life sciences, alongside other new investors HBM Partners, Hillhouse Capital, Sirona Capital and strategic investor Gilead. All current Hookipa investors, Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners participated in the round.
The proceeds of the fundraising will be primarily used to progress two proof-of concept clinical trials of Hookipa’s lead development programs, a phase 2 study of the Company’s prophylactic Cytomegalovirus (“CMV”) vaccine in solid organ transplant patients, and a phase 1 study of its TheraT® based active immunization therapy in patients with head & neck squamous cell carcinoma. In addition, Hookipa plans to expand its technology platform into other disease areas, such as prostate cancer.
Hookipa’s arenavirus-based vector technologies TheraT® and Vaxwave® have been designed to infect dendritic cells and stimulate potent and long-lasting immune responses. HB-101, the Company’s Vaxwave®-based CMV vaccine successfully completed a phase 1 trial earlier this year, demonstrating safety and immunogenicity. TheraT® has been shown to elicit uniquely potent antigen-specific CD8+ cytotoxic T cell responses and strong tumor control in mice. TheraT® works by delivering tumor-associated antigen-specific immunization alongside the release of the alarmin interleukin-33 (IL-33), which is key in stimulating potent and protective CD8+ cytotoxic effector T lymphocytes.
Joern Aldag, Chief Executive Officer of Hookipa said: “Our vision is of a world in which the immune system actively controls infectious diseases and cancer, using monotherapy or combinations of medications. We welcome the funding and support from this group of leading current and new investors, who have recognized the potential, versatility, and uniqueness of our novel viral vector platform in this context. This financing allows us to progress two lead development programs through the major inflection points of clinical proof of concept, and to expand our clinical work to additional virology and oncology indications.”
8957
wiener_biotech_hookipa_sichert_sich_knapp_60_mio_dollar_frisches_kapital
Was noch interessant sein dürfte:
Inbox: Raiffeisen rechnet mit besseren Kaufgelegenheiten
Inbox: Was kommende Woche in der Eurzone wichtig ist
Inbox: USA-Ausblick: Fed-Zinssitzung im Fokus
Inbox: "Schoeller is my top pick"
Inbox: VIG legt auch Gesellschaften in Kroatien zusammen
Inbox: Verbund-Aufsichtsrätin verkauft Aktien
Inbox: Buwog hat bei Roadshow überzeugt
Inbox: Wolford: In sechs bis acht Wochen gibt es eine Entscheidung
Wiener Börse Party #633: Heute April Verfall, Ex-Marinomed-Investor in Troubles und die Radio-Studios A, B, C und vielleicht D
Aktien auf dem Radar:Palfinger, Amag, SBO, Flughafen Wien, AT&S, Frequentis, EVN, EuroTeleSites AG, CA Immo, Erste Group, Mayr-Melnhof, S Immo, Uniqa, Bawag, Pierer Mobility, ams-Osram, Addiko Bank, Wiener Privatbank, SW Umwelttechnik, Oberbank AG Stamm, Kapsch TrafficCom, Agrana, Immofinanz, OMV, Österreichische Post, Strabag, Telekom Austria, VIG, Wienerberger, Warimpex.
Uniqa
Die Uniqa Group ist eine führende Versicherungsgruppe, die in Österreich und Zentral- und Osteuropa tätig ist. Die Gruppe ist mit ihren mehr als 20.000 Mitarbeitern und rund 40 Gesellschaften in 18 Ländern vor Ort und hat mehr als 10 Millionen Kunden.
>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner
Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab.
Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.
Newsletter abonnieren
Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)
per Newsletter erhalten
AT0000A2QS86 | |
AT0000A39UT1 | |
AT0000A2VYD6 |
Wiener Börse Party #618: Selbstbewusste FACC in einer Kategorie wohl Weltmeister, Strabag-Weg passt, Doppel-IPO, Andritz fehlt
Die Wiener Börse Party ist ein Podcastprojekt für Audio-CD.at von Christian Drastil Comm.. Unter dem Motto „Market & Me“ berichtet Christian Drastil über das Tagesgeschehen an der Wiener Börse....
Sebastián Bruno
Ta-ra
2023
ediciones anómalas
Carlos Alba
I’ll Bet the Devil My Head
2023
Void